Q3 2025 Amgen Inc Earnings Call Transcript
Key Points
- Amgen Inc (AMGN) reported a 12% year-over-year increase in revenues, reaching $9.6 billion, driven by strong performance across its key growth drivers.
- The company achieved a 14% volume growth, with 16 products delivering double-digit growth, showcasing the strength of its portfolio.
- Amgen Inc (AMGN) launched 'Amgen Now,' a direct-to-patient platform, enhancing access to its medicines at competitive prices.
- The company is making significant investments in manufacturing and R&D, with over $3 billion planned for the US this year, supporting long-term growth.
- Amgen Inc (AMGN) is advancing its pipeline with promising late-stage programs in obesity, cardiovascular disease, and rare diseases, indicating potential future growth.
- Despite strong revenue growth, Amgen Inc (AMGN) faces declining selling prices across the industry, which could impact future profitability.
- The company reported a non-GAAP operating margin of 47%, reflecting significant investments that may pressure margins in the short term.
- Amgen Inc (AMGN) anticipates increased competition for its product Prolia, which could negatively impact future sales.
- The company is experiencing a higher non-GAAP tax rate, which increased by 4.8 percentage points year over year to 18.2%.
- Amgen Inc (AMGN) faces challenges in the biosimilar market, with ongoing discussions about the effectiveness of the US biosimilar market and potential policy changes.
My name is Julianne and I will be your conference facilitator today for the Amgen Q3 2025 earnings conference call.
All lines have been placed on mute to prevent any background noise. There will be a question-and-answer session at the conclusion of the last speaker's prepared remarks. In order to ensure that everyone has a chance to participate, we would like to request that you limit yourself to asking one question during the Q&A session.
To ask a question, please press star from the number one on your telephone keypad to withdraw your question, please press one again.
I would now like to introduce Casey Caparelli, Vice President of investor relations. Mr. Caparelli, you may now begin.
Thank you, Julianne. And good afternoon, everyone. Welcome to our third quarter, 2025 earnings call.
Bob Bradway will lead the call and be followed by a broader review of our performance by Peter Griffith, Myrtle Gordon, and Jay Brattner.
Through the course of our discussion
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
